Business Wire

NY-ESTÉE-LAUDER

25.6.2020 14:02:08 CEST | Business Wire | Press release

Share
The Estée Lauder Companies Announces the Promotion of Jane Hertzmark Hudis To Executive Group President

This week, The Estée Lauder Companies (NYSE:EL) announced that Jane Hertzmark Hudis has been promoted to Executive Group President, effective July 1, 2020. She will continue to report directly to Fabrizio Freda, President and Chief Executive Officer, The Estée Lauder Companies (ELC), with brand portfolio oversight of Estée Lauder, La Mer, Bobbi Brown, AERIN, Origins, Aveda, Bumble and bumble, Dr. Jart+ and Do The Right Thing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200625005430/en/

As one of the most accomplished, visionary executives in the prestige beauty industry, Jane is highly regarded for her track record of building and leading global brands. In her elevated role, Jane’s portfolio reflects several of the highest growth areas of the Company, including skin care and driving success across China and APAC, as well as with Chinese consumers around the world.

“This well-deserved promotion recognizes Jane’s exceptional leadership across the Company,” said Mr. Freda. “Throughout her career, she has made a significant impact driving brand-building expertise, spearheading the elevation of marketing and talent, and leading her portfolio of brands to achieve outstanding broad-based growth across categories, regions and channels. I am grateful to Jane for all that she has done to drive the Company’s success and as an advisor to me, and I know that she will continue to lead and inspire us to even greater heights in the future.”

As an enterprise-wide leader, most recently as Group President, Jane has been the Company’s top skin care strategist, helping to drive expertise in this critical area. Today, Estée Lauder is the number one brand in skin care globally, and La Mer is the number one brand in luxury skin care globally. A champion of the Company’s hero franchise strategy, she has driven innovation and built iconic franchises including Estée Lauder’s Advanced Night Repair and La Mer’s Créme de La Mer. The outstanding results of her brands are a testament to her strategic vision, expertise in local relevance, exceptional talent for driving innovation in product and consumer marketing, and digital communication.

A passionate advocate of leadership development and inclusion and diversity throughout her career, Jane co-founded ELC’s Women’s Leadership Network in 2017 to inspire and engage women across the organization, helping them become exceptional leaders and mentors. In partnership with co-executive sponsors Tracey T. Travis, Executive Vice President and Chief Financial Officer and Sara E. Moss, Vice Chairman, Jane has expanded the Women’s Leadership Network to over 2,000 members globally, with local chapters in France and the United Kingdom.

Jane’s expertise has been widely recognized by many best-in-class organizations. She serves on the Board of Tiffany & Co. and as a Director of the Fashion Institute of Technology (FIT) Foundation, as well as on the Advisory Board of the Breast Cancer Research Foundation.

Prior to her promotion to Group President in 2016, Jane served for seven years as Global Brand President, Estée Lauder, where she led the brand’s modernization and digital evolution to attract a new generation of global consumers. She solidified Estée Lauder's position as a global leader in high-performance prestige skin care and makeup, growing net sales by more than 40 percent and establishing it as the number one brand in its prestige distribution in Asia. Preceding her leadership of Estée Lauder, Jane served in a number of key leadership roles at the Company, including President of Origins and BeautyBank, a brand innovation think tank she founded in 2003.

About The Estée Lauder Companies Inc.
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers and marketers of quality skin care, makeup, fragrance and hair care products. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Prescriptives, Lab Series, Origins, Tommy Hilfiger, M·A·C, Kiton, La Mer, Bobbi Brown, Donna Karan New York, DKNY, Aveda, Jo Malone London, Bumble and bumble, Michael Kors, Darphin, Tom Ford, Smashbox, Ermenegildo Zegna, AERIN, RODIN olio lusso, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, By Kilian, BECCA, Too Faced and Dr. Jart+.

ELC-C
ELC-B
ELC-L

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

LTM Has Issued an Offer to Acquire Randstad’s Technology and Consulting Services Business in Europe and Australia to Scale Domain-Driven Solutions and AI Services22.5.2026 07:09:00 CEST | Press release

The deal would be part of a 360° partnership with Randstad involving: Proposed acquisition of USD 500M+ (€469M) business, primarily across Aerospace & Defence, Automotive, Utilities and BFS Five-year IT services partnership to drive AI-enabled transformation for Randstad’s India Global Capability Center Strategic talent MSP to support LTM’s expanding global workforce LTM and Randstad announced that LTM has issued an offer to acquire Randstad’s Technology and Consulting Servicesbusiness in France, Germany, Belgium, Luxembourg and Australia, representing USD 500+ million (€469M) in annual revenue, to scale domain-driven solutions and AI services in the region. The proposed acquisition would expand LTM’s presence in key markets, primarily across Aerospace & Defence, Automotive, Utilities and BFS. It would enable local domain expertise and complementary regional capabilities in domain-driven digital engineering, cybersecurity and IoT, supported by onshore and nearshore delivery through cen

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases22.5.2026 07:00:00 CEST | Press release

Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region. “Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye